Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated with Metronomic Cyclophosphamide: A Clinical and Translational Prospective Study.

Benoîte MeryChristine Ménétrier-CauxLaure MontanéPierre-Etienne HeudelIsabelle Ray-CoquardThomas BachelotOlfa DerbelPaule AugereauIsabelle TreilleuxJustine BerthetAxelle NkodiaChristine Bardin-Dit-CourageotValery AttignonAnthony FerrariGwenaele GarinDavid PerolChristophe CauxBertrand DuboisOlivier Trédan

Published in: Breast cancer (Dove Medical Press) (2023)

Pembrolizumab combined with metronomic cyclophosphamide was well tolerated, and displayed limited anti-tumoral activity in lymphopenic MBC. Correlative translational data of our trial advocates for additional studies with other chemotherapy combinations.

Keyphrases

metastatic breast cancer
high dose
low dose
advanced non small cell lung cancer
study protocol
clinical trial
phase iii
electronic health record
big data
phase ii
randomized controlled trial
case control
machine learning
data analysis
open label
chemotherapy induced